28121744|t|Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma
28121744|a|Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.
28121744	0	10	Everolimus	T109,T121	C0541315
28121744	15	24	Treatment	T061	C0087111
28121744	28	63	Pseudomyogenic Hemangioendothelioma	T191	C0018915
28121744	64	99	Pseudomyogenic hemangioendothelioma	T191	C0018915
28121744	101	104	PMH	T191	C0018915
28121744	130	147	vascular neoplasm	T191	C0282607
28121744	181	192	soft tissue	T024	C0225317
28121744	222	234	young adults	T100	C0238598
28121744	236	246	Metastatic	T169	C1522484
28121744	247	250	PMH	T191	C0018915
28121744	258	263	fatal	T080	C1302234
28121744	281	290	effective	T080	C1704419
28121744	291	302	medications	T121	C0013227
28121744	318	322	case	T077	C1706256
28121744	340	343	boy	T100	C0870221
28121744	349	359	metastatic	T169	C1522484
28121744	360	363	PMH	T191	C0018915
28121744	369	391	responded to treatment	T201	C0521982
28121744	397	407	everolimus	T109,T121	C0541315
28121744	411	450	mammalian target of rapamycin inhibitor	T121	C2746052
28121744	452	472	Immunohistochemistry	T060	C0021044
28121744	485	514	mammalian target of rapamycin	T116,T126	C1307407
28121744	519	528	expressed	T045	C1171362
28121744	532	535	PMH	T191	C0018915
28121744	536	552	biopsy specimens	T024	C0677862
28121744	576	585	reduction	T080	C0392756
28121744	589	592	PMH	T191	C0018915
28121744	593	603	tumor size	T082	C0475440
28121744	614	623	treatment	T061	C0087111